Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany
Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Anticancer Res. 2021 Oct;41(10):5081-5087. doi: 10.21873/anticanres.15324.
Pharmacological inhibition of osteoclast activity is an essential component of oncological therapy for patients with bone metastases. In rare cases, medication-related osteonecrosis of the jaws (MRONJ) is observed. MRONJ can cause bone defects not inferior to primary or metastatic jaw neoplasms. Oral examination of patients on osteoclast-inhibiting medication aims to identify risk factors at an early stage and to initiate therapy. The current focus on osteoclast-inhibiting drugs in the maxillofacial region is MRONJ. Effects of the substances other than MRONJ are rarely reported.
The female patient with metastatic breast cancer had developed extensive osteolysis of the mandibular ramus at the time of initial diagnosis. The patient was treated with denosumab. Seven months later, a significant reduction in the mandibular osteolytic zone was recorded. However, known bone metastases from other sites had increased in size during multimodal therapy, and further metastases were recorded.
Jaw metastasis can shrink under denosumab therapy.
抑制破骨细胞活性的药物是治疗骨转移患者的肿瘤学治疗的重要组成部分。在极少数情况下，会观察到药物相关性颌骨坏死（MRONJ）。MRONJ 可导致不亚于原发性或转移性颌骨肿瘤的骨缺损。对接受破骨细胞抑制剂治疗的患者进行口腔检查旨在早期识别风险因素并开始治疗。目前，人们对颌骨区域的破骨细胞抑制剂的关注集中在 MRONJ 上。很少有关于这些物质的除 MRONJ 以外的作用的报道。
这位患有转移性乳腺癌的女性患者在初始诊断时就出现了下颌支广泛的骨质溶解。该患者接受了地舒单抗治疗。七个月后，下颌骨骨质溶解区明显缩小。然而，在多模式治疗期间，其他部位已知的骨转移灶增大，并记录到进一步的转移。
颌骨转移灶可在地舒单抗治疗下缩小。
